Fig. 6

Pharmacological inhibition of PDE3A and inflammation-induced CMH development. Significant increase in LPS-induced PB-positive CMH number (a), size (b), and area (c) in the WT mice compared with PBS controls. Representative images of PB-positive lesions (indicated by arrows) in WT controls, mice treated with LPS or with LPS and cilostazol (d). No effect of cilostazol treatment on any of these CMH parameters. Data are presented as mean ± SEM. Statistical test: one-way ANOVA with Bonferroni’s post-test or Kruskal-Wallis test with Dunn’s post-test. *p < 0.05, **p < 0.01